Ranibizumab for the management of Sorsby fundus dystrophy

Eye (Basingstoke)

Volumn 27, Issue 1, 2013, Pages 101-102

  Balaskas, K ^a   Hovan, M ^a   Mahmood, S ^a   Bishop, P ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; CASE REPORT; DNA DETERMINATION; FLUORESCENCE ANGIOGRAPHY; GENE MUTATION; HUMAN; LASER COAGULATION; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETINA DYSTROPHY; RETINA MACULA HEMORRHAGE; SNELLEN CHART; SORSBY FUNDUS DYSTROPHY; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 84872246066     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.221     Document Type: Letter

References (5)

1. Sivaprasad S, Webster A, Egan C, Bird A, Tufail A. Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol 2008; 146: 228-234.
2. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994; 8: 352-356. (Pubitemid 24375600)
3. Holz FG, Haimovici R, Wagner DG, Bird AC. Recurrent choroidal neovascularization after laser photocoagulation in Sorsby's fundus dystrophy. Retina 1994; 14: 329-334. (Pubitemid 24310150)
4. Peiretti E, Klancnik JM Jr, Spaide RF, Yannuzzi L. Choroidal neovascularization in Sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina 2005; 25: 377-379. (Pubitemid 40517374)
5. Prager F, Michels S, Geitzenauer W, Schmidt-Erfurth U. Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin). Acta Ophthalmol Scand 2007; 85(8): 904-906. (Pubitemid 350142818)